Actinium Pharmaceuticals shares gain momentum as new clinical data from EANM 2026 confirms ATNM-400's broad antitumor activity across diverse cancer models, including NSCLC and colorectal indications.
Actinium Pharmaceuticals is showcasing significant clinical progress for ATNM-400 at the EANM 2026 conference, demonstrating broad antitumor efficacy across diverse cancer models including KRAS- and ALK-driven non-small cell lung cancer (NSCLC). By building on previous EGFR-mutant findings, the company is positioning ATNM-400 as a mutation-agnostic therapeutic candidate with the potential to improve standard-of-care responses in colorectal cancer.
The presentations highlight the broad antitumor activity of ATNM-400 across multiple cancer models, supporting a mutation-agnostic development strategy.
The data covers KRAS- and ALK-driven NSCLC models, EGFR-mutant findings, and colorectal cancer.
Actinium Pharmaceuticals announced upcoming oral and poster presentations at EANM 2026 showcasing the broad antitumor efficacy of ATNM-400. The data highlights the drug's potential across multiple cancer models, including KRAS- and ALK-driven non-small cell lung cancer, reinforcing its mutation-agnostic development strategy.
The data confirms the drug's efficacy across various cancer mutations, suggesting it could be a versatile treatment option beyond specific genetic drivers.